| Literature DB >> 26117365 |
Maude Beaudoin-Gobert1, Justine Epinat1, Elise Météreau1, Sandra Duperrier1, Sara Neumane1, Bénédicte Ballanger1, Franck Lavenne2, François Liger2, Christian Tourvielle2, Frédéric Bonnefoi2, Nicolas Costes2, Didier Le Bars3, Emmanuel Broussolle4, Stéphane Thobois5, Léon Tremblay1, Véronique Sgambato-Faure6.
Abstract
Serotonergic (5-HT) neurons degenerate in Parkinson's disease. To determine the role of this 5-HT injury-besides the dopaminergic one in the parkinsonian symptomatology-we developed a new monkey model exhibiting a double dopaminergic/serotonergic lesion by sequentially using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 3,4-methylenedioxy-N-methamphetamine (MDMA, better known as ecstasy). By positron emission tomography imaging and immunohistochemistry, we demonstrated that MDMA injured 5-HT nerve terminals in the brain of MPTP monkeys. Unexpectedly, this injury had no impact on tremor or on bradykinesia, but altered rigidity. It abolished the l-DOPA-induced dyskinesia and neuropsychiatric-like behaviours, without altering the anti-parkinsonian response. These data demonstrate that 5-HT fibres play a critical role in the expression of both motor and non-motor symptoms in Parkinson's disease, and highlight that an imbalance between the 5-HT and dopaminergic innervating systems is involved in specific basal ganglia territories for different symptoms.Entities:
Keywords: Parkinson’s disease; dyskinesia; monkey; neuropsychiatric symptoms; serotonin
Mesh:
Substances:
Year: 2015 PMID: 26117365 DOI: 10.1093/brain/awv183
Source DB: PubMed Journal: Brain ISSN: 0006-8950 Impact factor: 13.501